Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Novavax, Inc. (NASDAQ:NVAX ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Ruxandra Draghia-Akli - EVP and Head of Research & Development John Charles Jacobs Are we ready to go? Are we live?
Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Novavax (NVAX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
Novavax Stock Soars on FDA Approval for COVID Vaccine
Biotech stock Novavax Inc (NASDAQ:NVAX) is skyrocketing today, up 26% at $8.48 at last glance, after the U.S. Food & Drug Administration (FDA) approved the company's COVID-19 vaccine.
